Expansion of government support for drug discovery and regenerative medicine infrastructure
First written in FY2025-H1. 3 of 4 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「The Japanese government has also introduced support measures aimed at strengthening drug discovery capabilities. The Ministry of Education, Culture, Sports, Science and Technology has identified stronger R&D support for medical and life sciences research, promotion of cross-disciplinary basic research to create innovative seeds, and development of systems in preparation for infectious disease emergencies as priority measures. The Ministry of Health, Labour and Welfare prioritises strengthening the drug discovery ecosystem, addressing new modalities and promoting the commercialisation of promising seeds as pharmaceuticals and medical devices. The Ministry of Economy, Trade and Industry has identified promoting the domestic production of pharmaceuticals and regenerative medicine products, developing biotechnology industry hubs and providing technical support, and supporting the commercialisation efforts of biotechnology ventures as priority measures.」
The support environment for government measures to strengthen drug discovery capabilities, including the priority measures of the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labour and Welfare and the Ministry of Economy, Trade and Industry, is reaffirmed. - 2026-03-11RestatedEarnings
「The Japanese government has also implemented support measures aimed at strengthening drug discovery capabilities」
Government support measures to strengthen drug discovery capabilities and promote commercialization were reconfirmed as part of the industry environment. - FY2025RestatedAnnual report
「The Japanese government has also introduced support measures aimed at strengthening drug discovery capabilities. The Ministry of Education, Culture, Sports, Science and Technology has identified measures including stronger R&D support for medical and life sciences research, promotion of cross-disciplinary basic research to create innovative seeds, and development of systems in preparation for infectious disease emergencies.」
Government policies to strengthen drug discovery capabilities, basic research, the commercialisation of innovative seeds and support for the biotechnology industry are reaffirmed, with additional explanations of the priority measures of the relevant ministries. - FY2025-H1First statedAnnual report
「The government has introduced support measures aimed at strengthening drug discovery capabilities, and the Ministry of Health, Labour and Welfare included ¥53.513 billion in its FY2025 budget for biotechnology-related initiatives, up 0.1% from the previous fiscal year. Key measures include strengthening the drug discovery ecosystem, addressing new modalities and supporting medical device development, with particular emphasis on support for the commercialisation of drug discovery seeds (¥3 billion), development of facilities for drug discovery clusters (¥7 billion) and strengthening the AI-enabled drug discovery infrastructure (¥3.5 billion).」
Specific government measures to strengthen drug discovery capabilities, including the FY2025 biotechnology-related budget, support for the commercialisation of drug discovery seeds, development of drug discovery clusters and strengthening of the AI-enabled drug discovery infrastructure, are stated for the first time.